Jan 28

Guilt Free Desserts

Posted on January 28, 2012 by admin

Guilt Free Desserts
50 Simple Recipes You Can Use To Whip-up All-natural, Gluten-free, Diabetic-safe, Mouthwatering Desserts
Guilt Free Desserts

Dec 10

Afatinib (BIBW 2992*) Triples Progression Free Survival in Lung Cancer Patients

Posted on December 10, 2011 by admin

Boehringer Ingelheim announced promising results from two clinical trials of its investigational cancer compound afatinib (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy. Results from the LUX-Lung 1 trial suggest that afatinib (BIBW 2992) is highly active in late-stage patients with NSCLC1, while in the LUX-Lung 2 phase II trial afatinib demonstrated encouraging activity in advanced NSCLC patients that have a mutated EGF Receptor.

Afatinib, which is taken as a tablet, is a next generation inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) tyrosine kinase (TK) and unlike first generation TKIs irreversibly binds to EGFR/HER2. The compound is under development in several solid tumour types.

The LUX-Lung 1 trial (phase II b/III) compared afatinib to placebo in over 580 patients with advanced NSCLC whose disease has progressed after receiving chemotherapy and a first-generation EGFR Tyrosine Kinase Inhibitor (gefitinib or erlotinib) results showed1:

* Even though the LUX-Lung 1 trial did not meet the primary endpoint of prolonging overall survival (OS), afatinib significantly extended the time before the tumour progressed; specifically it led to a three-fold extension of progression-free survival (PFS, key secondary endpoint) from 1.1 months to 3.3 months over placebo.
* The PFS benefit was apparent as a robust effect across all patient subgroups and has been confirmed by independent review.
* There was a significantly higher rate of tumour control or shrinkage in those patients who took afatinib (disease control rate: 58%) versus those taking placebo (disease control rate: 19%); also independently verified.
* Afatinib significantly improved the lung-cancer related symptoms cough, dyspnea (shortness of breath) and pain, and delayed the time to deterioration of cough, individual dyspnea items and chest pain significantly.
* There were no new or unexpected safety findings; the main side effects were diarrhea and rash.

Conclusions from the trial will be relevant for the design of further clinical studies, which will evaluate further patient populations and their mutation status.

Lung cancer is the most common and most deadly form of cancer in the world, accounting for 1.6 million new cancer cases annually and 1.4 million deaths2 from lung cancer. Lung cancer remains an area of high unmet need, especially in its advanced stages where it is particularly aggressive and patients have limited treatment options. No approved therapy is currently available for patients with advanced lung cancer who have failed chemotherapy and progressed after treatments with EGFR TKI.

In clinical practice, it is of high relevance to patients to have improvement in key lung cancer related symptoms such as cough, shortness of breath and pain? commented Dr Vera Hirsh, investigator of the trial, and Chair of the Lung Cancer Committee, McGill University, Canada. Furthermore, the time to deterioration, meaning the time before the symptoms get worse, was significantly extended for some of these symptoms in the LUX Lung 1 study.

This is the first time that a compound has demonstrated in a controlled study, a clinically meaningful improvement in PFS in patients with NSCLC who have progressed on first generation EGFR TKIs.

Encouraging results were also presented for LUX-Lung 2, a phase II trial studying patients with advanced NSCLC who harbour EGFR mutations. This result shows that the use of afatinib led to a high rate of tumour size reduction (overall response rate of 61%) and a long delay in the progression of cancer by over 1 year (PFS of 14 months)3. These results help to underline afatinib?s potential benefit as a first or second line treatment in patients with EGFR mutations. Two phase III trials, LUX-Lung 3 and LUX-Lung 6 are currently underway to further evaluate afatinib as a first-line treatment in this patient group.

Afatinibs clinical trial programme: LUX Trial Programme

The LUX-trial programme is a comprehensive and robust programme that comprises more than ten trials conducted across the globe, investigating afatinib in a variety of different solid tumour types, including NSCLC, breast and head and neck cancer.

LUX-Lung 1 is a phase III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with chemotherapy and first generation EGFR-TKIs, erlotinib or gefitinib.

LUX-Lung 2 is a phase II trial evaluating afatinib in NSCLC patients with EGFR mutations, either chemotherapy naïve or after one line of chemotherapy.

In two further ongoing global phase III trials, LUX-Lung 3 and LUX-Lung 6, the efficacy and safety profile of afatinib is compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations in different geographical regions.

Another trial, LUX-Lung 5, is a global phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomised phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may further benefit from afatinib beyond progression when given in combination with chemotherapy.

Further indications

Additionally, Boehringer Ingelheim has recently commenced a phase III clinical trial evaluating afatinib in advanced breast cancer (LUX-Breast 1).

Afatinib is also being investigated in head and neck cancer, glioblastoma and colorectal cancer.

Afatinib & BIBF 1120*: the two front-runner molecules within Boehringer Ingelheim?s investigational oncology portfolio

Apart from afatinib, Boehringer Ingelheim?s late stage oncology portfolio includes BIBF 1120, also in phase III development for the treatment of patients in two different indications, advanced NSCLC and ovarian cancer.

BIBF 1120 is a triple angiokinase inhibitor that acts on three growth factors simultaneously: vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR) all crucially involved in the formation of blood vessels, which supply tumours with nutrients and oxygen needed for the cancer to grow.

About lung cancer

Lung cancer is the world’s most common cancer and kills more people than any other cancer.In 2008, approximately 1.6 million new cases of lung cancer were diagnosed worldwide, with 1.4 million people dying from the disease.2

About breast cancer

There are more than one and a half million cases of breast cancer diagnosed each year4. It is the leading cause of cancer deaths in women worldwide, resulting in more than 500,000 deaths per year. Breast cancer accounts for around a third of all cancers diagnosed in women, making it the most commonly diagnosed tumour type in females5.

About head and neck cancer

Head and neck cancer can occur in over 30 different places in any of the tissues or organs in the head and neck6 and is the sixth most frequently occurring cancer worldwide7. Most head and neck cancers are squamous cell carcinomas8 over 90% of which express EGFR9 which is critical for tumour growth.10

About ovarian cancer

Each year approximately 204,000 new cases of ovarian cancer are diagnosed in women worldwide, with an estimated 125,000 dying of the disease each year11. One of the greatest challenges in the management of ovarian cancer is that the majority of cases are not found at an early stage11 (when definitive cure is possible by surgery) since the tumour usually causes only non-specific symptoms, commonly attributed to non-serious causes.

Boehringer Ingelheim announced promising results from two clinical trials of its investigational cancer compound

afatinib (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

Results from the LUX-Lung 1 trial suggest that afatinib (BIBW 2992) is highly active in late-stage patients with

NSCLC1, while in the LUX-Lung 2 phase II trial afatinib demonstrated encouraging activity in advanced NSCLC patients

that have a mutated EGF Receptor.

Afatinib, which is taken as a tablet, is a next generation inhibitor of the epidermal growth factor receptor (EGFR)

and human epidermal receptor 2 (HER2) tyrosine kinase (TK) and unlike first generation TKIs irreversibly binds to

EGFR/HER2. The compound is under development in several solid tumour types.

The LUX-Lung 1 trial (phase II b/III) compared afatinib to placebo in over 580 patients with advanced NSCLC whose

disease has progressed after receiving chemotherapy and a first-generation EGFR Tyrosine Kinase Inhibitor (gefitinib

or erlotinib) results showed1:

* Even though the LUX-Lung 1 trial did not meet the primary endpoint of prolonging overall survival (OS),

afatinib significantly extended the time before the tumour progressed; specifically it led to a three-fold extension

of progression-free survival (PFS, key secondary endpoint) from 1.1 months to 3.3 months over placebo.
* The PFS benefit was apparent as a robust effect across all patient subgroups and has been confirmed by

independent review.
* There was a significantly higher rate of tumour control or shrinkage in those patients who took afatinib

(disease control rate: 58%) versus those taking placebo (disease control rate: 19%); also independently verified.
* Afatinib significantly improved the lung-cancer related symptoms cough, dyspnea (shortness of breath) and pain,

and delayed the time to deterioration of cough, individual dyspnea items and chest pain significantly.
* There were no new or unexpected safety findings; the main side effects were diarrhea and rash.

The results of LUX-Lung 1 in a special patient population whose cancers probably have a high incidence of EGFR

mutations have substantially contributed to better understanding of the biology of these tumours. Conclusions from

the trial will be relevant for the design of further clinical studies, which will evaluate further patient

populations and their mutation status.

Lung cancer is the most common and most deadly form of cancer in the world, accounting for 1.6 million new cancer

cases annually and 1.4 million deaths2 from lung cancer. Lung cancer remains an area of high unmet need, especially

in its advanced stages where it is particularly aggressive and patients have limited treatment options. No approved

therapy is currently available for patients with advanced lung cancer who have failed chemotherapy and progressed

after treatments with EGFR TKI.

In clinical practice, it is of high relevance to patients to have improvement in key lung cancer related symptoms

such as cough, shortness of breath and pain? commented Dr Vera Hirsh, investigator of the trial, and Chair of the

Lung Cancer Committee, McGill University, Canada. Furthermore, the time to deterioration, meaning the time before the

symptoms get worse, was significantly extended for some of these symptoms in the LUX Lung 1 study.

This is the first time that a compound has demonstrated in a controlled study, a clinically meaningful improvement in

PFS in patients with NSCLC who have progressed on first generation EGFR TKIs.

Encouraging results were also presented for LUX-Lung 2, a phase II trial studying patients with advanced NSCLC who

harbour EGFR mutations. This result shows that the use of afatinib led to a high rate of tumour size reduction

(overall response rate of 61%) and a long delay in the progression of cancer by over 1 year (PFS of 14 months)3.

These results help to underline afatinib?s potential benefit as a first or second line treatment in patients with

EGFR mutations. Two phase III trials, LUX-Lung 3 and LUX-Lung 6 are currently underway to further evaluate afatinib

as a first-line treatment in this patient group.

Afatinibs clinical trial programme: LUX Trial Programme

The LUX-trial programme is a comprehensive and robust programme that comprises more than ten trials conducted across

the globe, investigating afatinib in a variety of different solid tumour types, including NSCLC, breast and head and

neck cancer.

LUX-Lung 1 is a phase III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in

NSCLC patients who were previously treated with chemotherapy and first generation EGFR-TKIs, erlotinib or gefitinib.

LUX-Lung 2 is a phase II trial evaluating afatinib in NSCLC patients with EGFR mutations, either chemotherapy naïve

or after one line of chemotherapy.

In two further ongoing global phase III trials, LUX-Lung 3 and LUX-Lung 6, the efficacy and safety profile of

afatinib is compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations in

different geographical regions.

Another trial, LUX-Lung 5, is a global phase III trial in patients previously treated with erlotinib or gefitinib.

This is the first randomised phase III trial investigating whether patients who initially benefit from treatment with

afatinib alone may further benefit from afatinib beyond progression when given in combination with chemotherapy.

Further indications

Additionally, Boehringer Ingelheim has recently commenced a phase III clinical trial evaluating afatinib in advanced

breast cancer (LUX-Breast 1).

Afatinib is also being investigated in head and neck cancer, glioblastoma and colorectal cancer.

Afatinib & BIBF 1120*: the two front-runner molecules within Boehringer Ingelheim?s investigational oncology

portfolio

Apart from afatinib, Boehringer Ingelheim?s late stage oncology portfolio includes BIBF 1120, also in phase III

development for the treatment of patients in two different indications, advanced NSCLC and ovarian cancer.

BIBF 1120 is a triple angiokinase inhibitor that acts on three growth factors simultaneously: vascular endothelial

growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor

(FGFR) all crucially involved in the formation of blood vessels, which supply tumours with nutrients and oxygen

needed for the cancer to grow.

About lung cancer

Lung cancer is the world’s most common cancer and kills more people than any other cancer.In 2008, approximately 1.6

million new cases of lung cancer were diagnosed worldwide, with 1.4 million people dying from the disease.2

About breast cancer

There are more than one and a half million cases of breast cancer diagnosed each year4. It is the leading cause of

cancer deaths in women worldwide, resulting in more than 500,000 deaths per year. Breast cancer accounts for around a

third of all cancers diagnosed in women, making it the most commonly diagnosed tumour type in females5.

About head and neck cancer

Head and neck cancer can occur in over 30 different places in any of the tissues or organs in the head and neck6 and

is the sixth most frequently occurring cancer worldwide7. Most head and neck cancers are squamous cell carcinomas8

over 90% of which express EGFR9 which is critical for tumour growth.10

About ovarian cancer

Each year approximately 204,000 new cases of ovarian cancer are diagnosed in women worldwide, with an estimated

125,000 dying of the disease each year11. One of the greatest challenges in the management of ovarian cancer is that

the majority of cases are not found at an early stage11 (when definitive cure is possible by surgery) since the

tumour usually causes only non-specific symptoms, commonly attributed to non-serious causes.

Read Related Topics on Breast Cancer and Cancer Care News .

Fireside Gourmet Fat Free Caramel Mochaccino Instant Flavored Coffee – Portion of Sale for Breast Cancer Research

Posted on September 7, 2011 by admin

Fireside Gourmet Fat Free Caramel Mochaccino Instant Flavored Coffee – Portion of Sale for Breast Cancer Research

Fireside Coffee gourmet instant flavored coffee assortment mix of gourmet drinks – Just add water!
Creamy caramel flavor blended with chocolate and coffee createhe most delicious flavor to date!
This canister serves 14 eight ounce cups of coffee by just adding a few scoops to hot water.
Great to give as a gift or to serve at holiday parties to get great raves.
Fat Free premium instant coffee packed with flavor that you’ll love.

Next time you are craving a treat, don’t reach for a candy bar or ice cream, instead heat up some water and blend in some of this delicious Fat Free Caramel Mochaccino coffee. Creamy caramel flavor blended with chocolate and coffee createhe most delicious flavor to date! For each package of Caramel Mochaccino sold, Fireside Coffee will donate a portion of the proceeds to the National Breast Cancer Foundation. This canister has 14 servings of instant coffee that can make 8 ounce cups of coffee

List Price: $ 7.25

Price:

Battery Tender Plus 12-Volt / 1.25-Amp Battery Charger, Pink

12 volt 1.25 amp performance
Constant current recharge
Float charge at the end of the charge cycle
Fully automatic
Pink color; 10% of all proceeds go to breast cancer research

Battery Tender Plus 12 V 1.25 Amp Battery Charger is the most advanced charger/maintainer on the market especially designed for today’s sealed lead acid batteries. It uses micro-processor technology in a four stage charging profile to charge, improve and float your battery. Constant current charging and regulated voltage patterns allows the battery to be recharged fully and safely without the fear of overcharging. When you purchase this item, 10% of all proceeds go to breast cancer research.The

List Price: $ 69.95

Price: $ 49.95

<p>Your browser does not support iframes.</p>

Aug 30

Free Alternative Program For Cancer Treatment

Posted on August 30, 2011 by admin

Walking along the beach in Cartagena I was looking for a story to write for my mid semester project. After talking to several people I stumbled upon an interesting gentleman named Pablo Hernando, and referred to as DrPablo by the loving people surrounding him at the beach. These people all have or had cancer and are undergoing the XYZ-Wellbeing ReTreat Facility Program in a Temporary Accommodation here in Cartagena Colombia at a cost of 0,000.00 and although they haven’t completed their program yet, the felt very happy with the service and treatments they had undergone.
Some claimed that the Cancer lumps had completely gone or softened. Bone cancer that was aggressively growing had completely stopped after the first month. Breast lumps that had metastasized to the lunge completely gone after two months, mouth, throat and brain tumor shrinking after one month, lymphoma lumps Â½ in size month one. These neoplasm’s stories were astounding. So I choose this interesting, humble, sophisticated looking, olive skinned, charismatic man for my story, and what I got was so much more than I expected, I think you will agree with his patients, he is a special person, please read on.
DrPablo Hernando from XYZ-Wellbeing Cancer ReTreat Facility is proposing that a Free Cancer Trial be done to once and for all take away the myth of Alternative and Complementary Therapies.
“Having worked for 11 years in the industry, I believe with-out question many people suffering the turmoil of decision making over what to do when the traditional chemotherapy has failed, or better still, should I be doing the Alternative Therapy First?

This trial will make it easier for both the people with cancer and there loving family to understand.”

Brain Cancer
Neck and Above Cancer
Breast Cancer
Large Cell Lung Cancer
Stomach Cancer
Pancreas Cancer
Other behind Ribcage Cancer
Small â Large Colon or Rectum Cancer
Liver Cancer
Prostate Cancer
Ovarian Cancer
Other Cancers below the Ribcage
Bone Cancer
Skin Cancer
Other Cancers in the legs
Lymphoma Cancers

A) Primary only = Size = Aggressiveness = Sex = Amount of Cancer = Patients Health
Hypotheses! If the cancer went with-in 7 days would the person survive?
Yes = intensive three month program in clinic trial
(Continue Application)
No = three months home treatment self funded, followed by the in clinical trial
(Re Apply if improvement is seen based on Three Month Home Program Results)

Yes = intensive three month program in clinic trial (Continue Application)
No = three months home treatment self funded, followed by the in clinical trial
(Re Apply if improvement is seen based on Three Month Home Program Results)

B) Age 100 point ID =Drivers License and Birth Certificate and Photo ID
Accountant Financial Statement to determine if the family can afford the flights etc and it will not leave other family members in financial difficulty.
C) The health of the patient. (Special assessment form)
D) Any treatments done to date. ( All reports to date and any special requested reports)
E) The family’s acceptance that this is a trial, expectations-outcomes are unknown.
F) Letter from local oncologist confirming diagnoses with accompanying evidence and requested blood work and reports.
G) Letter from a psychologist stating that the patient and family are aware and understand what a trial is, and that they understand our Disclaimer, For Your Information Sheet, published on the website and that them and their family will except our choice to discontinue, modify and or change treatment if we choose. That the applicant and family are of sound mind and in agreement for the patient to do this trial.
H) They can afford any fees, if applicable such as travel and accommodation in the medical center if not covered under the trial. This rate would be similar to what most modern hospitals charge for an Intensive Private Room (up to 00 USD per day, however we are negotiating a place that could be as low as a few thousand a week). The facility we propose to use will adjust the fee based on an income test of the family and assets of the patient and partner if it is not funded by us, if applicable.
I) It is also proposed, again based on the income test that those that become cancer free agree to pay a 10% of income over the following 5 years to cover ongoing follow-up and offset our costs so we can offer the program to more people if results show benefit.
Where would this trial take place?
“At our new clinic when completed in Cartagena Colombia, this would halve the accommodation cost, or if not opened by the time we start, any other care center or hospital that has the facilities. “Hospitals may submit “Offer to accommodate and support trial” he said. The 300 acre property proposed is being assessed at the moment DrPablo said, “with the building design underway, we hope commencement will be later this year.”

“The rooms are fully self contained units, with a small extra room and bunk bed off the side for a family member or friend. Fresh Juices are delivered to your room and all meals will be catered for.”
Are the meals organic?
We try to only supply organic, however until our own private gardens are giving us produce, we can only say that most of the food is organic and it is all purchased freshly each day, from the local markets.
THE TREATMENT
After your application is acceptable, keeping in mind the normal cost of this treatment is 0,000 with a 50% refund or repeated program offered if not successful. You will arrive and after settling into your room, done on a Friday, a tour of the facilities, understanding meals, cleaning, etc on Saturday, Sunday is induction and a 2 x 2 hour Learning Workshop.

The 1st stage of treatment starts on Monday and you, along with another 50 patients all have a roster to follow. Laetrile â B17, Vitamin C Intensive 120grams followed by Hyperbaric Chamber Treatment, Hypothermia Treatment along with a few other special treatments, herbs and poultices.
Blood tests and scans are done as required weekly and at the end of each 21 days. Every day of therapies is arranged so you don’t overdo things, and include the very intensive treatments alongside what we call pampering treatments such as massage and spa’s.
This is continued for THREE WEEKS, then a week’s rest, some site seeing, dancing and calibrating life goes on. This is also visiting time and open house to the rest of your family.

Stage two, Induction is repeated as at stage 1, along with the workshop. Those at stage two will meet those starting stage one. Again questions and answers and the tour etc alone with a detailed workshop.
The 2nd Stage of treatment is very different from Stage one in that many of the other therapies stop or slow down, except the laetrile. Emotional Therapies are added and treatment commenced. This is also the High PH Treatment and Ozone IV Treatment Stage. This is the aggressive cancer fighting Therapy in this stage.
Depending on the patient, the High PH Therapy is done for either 21 days in a row or 11 days then 3 days rest, then a second 11 days. The three days in the middle would only have Hyperbaric Treatment, pampering and relaxation massages and Spa’s if recommended.

After a week’s brake from therapies, a full P.E.T. Scan is done, blood work are retested to see how things are progressing.
Based on this report, a program will be designed for stage 3, expected rebuilding Oxygen Therapies, more Vitamin C, possibly a little ozone etc.
Sometimes we may order a biopsy to see if any cancer left is alive or dead and if so any changes to it.
After the third month 21 days the clients leave that weekend, the care facility is fully disinfected, Ozonized air purifiers ran for 3 days with no one in the building, this is to keep the facility clean from what most hospitals around the world now have out of control, Golden Staph. Said DrPablo. (Staphylococcus aureus, or S. aureus, is sometimes called ‘golden staph’. It is a common bacterium that lives on the skin or in the nose. It can cause a range of mild to severe infections and may cause death. Some strains are resistant to antibiotics. Hospital patients are more likely to be infected by S. aureus because of surgical or other wounds.)

We hope that a philanthropist comes forward to help with this much needed research. The foundations of the program have been tested. DrPablo Said, However never in a controlled environment, with many at the same time with the same cancer has ever been done; we will lean so much from this a trial.
Possibly it would be NEWS WORTHY and a documentary of all the patients would be a very high rating TV documentary, possibly this could attract millions to make this happen. I just hope in my life time and with my life experiences, I can be a part of what I think will be an historic moment in medicine and Cancer Treatment.

This is a draft recommendation to our team of caring people who want to make a change in cancer treatment options. It will come and attract criticisms and possibly slander as alternative practices often do. But how do we get to prove or disprove a program without this type of trial?
It doesn’t matter if you are rich or poor, old or young, cancer will sneak its way into your life. Not one family alive today in modern countries will avoid it. So I ask you simply this, what are you waiting for?
The return will not be in cash; however it still will be the best investment you ever make for you and your families future wellbeing. People are driving cars worth 0′s of thousands. If the car was to break down, I believe they wouldn’t be walking for long!

It will teach us how to avoid or pre-treat potential cancers if we are successful. The one funny thing about prevention when people do it, they never know if the investment worked for them or not.
Something to think about… The Cancer Fund-raising Machines have put millions into the same old thing; the only main benefit to come out of that investment has been early detection.
Give Alternative Therapies a chance and I believe no-one will be disappointed except those making drugs for the traditional programs of chemotherapy and radiation.
God Bless all those with cancer and also god forgive those who have been blinded by over education.
(DrPablo) If you had been a witness to what I have seen, you would be like me, determined to prove it!

If you want a free consultation go to the contact us link on the website and click on the, designed for people with cancer to apply for the or go on the waiting list for the trial.
DrPablo gave me some hand outs and warnings that he asked be put at the bottom of my interview, they are below.

Laetrile, Vitamin B17, Amygdaline should never be given in a drip mixed with Vitamin C
High PH Therapy should only be done at home if you have a 24 hour consultant that is contactable helping you.
Before doing Keith Brewer’s or anyone’s online program it is a must to strengthen your body and immune system one month before High PH Therapy.
Below is a good healthy support shake that everyone should take, it will not put on weight, however we have witnesses in most cases it does stop weight loss, often seen in Cancer Patients.

Click here to download PDF
http://xyz-wellbeing.com/images/2011_IMAGES/How_to_Make_the_XYZ_Wellbeing_Cancer_ReTreat_Facility_Yummy_Shake.pdf

Click Here to download a MS Word Copy
http://xyz-wellbeing.com/images/2011_IMAGES/How_to_Make_the_Yummy_Shake.docx

http://www.xyz-wellbeing.com

http://www.xyz-wellbeing.com/xyz-wellbeing-company-info/xyz-about-the-company/about-us.html

http://www.xyz-wellbeing.com/the-xyz-services-we-offer/xyz-alternative-cancer-retreat-facility-services/retreat-services.html

http://www.xyz-wellbeing.com/latest/the-xyz-retreat-cancer-facility-news/xyz-wellbeing-manual-index.html

http://www.xyz-wellbeing.com/news/lead-story1/a-cesium-b17-cancer-program.html

or paying a few thousand and starting a home program now…
https://fs7.formsite.com/xyz-wellbeing-questions/form8/secure_index.html

The XYZ Wellbeing Cancer Facility is also looking for Investors. Expecting a return of over 50% per annum with-in 3 years. With the company able to buy back your shares if it pays you up with a 100% return per annum. That even has me interested. They need 3 million to get up and running and another few million to do this trial, then the workload will sore… After seeing what these clients think of the program, it all has me interested.

https://fs7.formsite.com/xyz-wellbeing-questions/form9/secure_index.html

Copied from the website, I thought that this was good and also important to share with you all.

The information within the XYZ-Wellbeing web site is intended to explain in brief the services on offer,
to pre-educate and help both referring practitioners and patients make better health care decisions
and enable patients to take greater responsibility for their own well-being.
The information provided in links from this Website is independent and does not constitute a medical recommendation.
If you find any misinformation or inappropriate material from these links, please report them to us immediately.
All information is intended for research and educational purposes only,
and no claims, either real or implied, are being made.

as we combine synergistic many Alternative Programs.
We will publish our Research Results from the XYZ-Wellbeing ReTreat Facility,
as this will be a controlled environment, something not available to us in the past.
Government agencies would rather we withhold these stories from the public because,
allegedly, they constitute “unproven medical claims.”

the only claims we make are that this information is authentic
and that the people who wrote them or videoed them were genuine people
and that it is their information as they said it, felt it and believed it, and they are real stories and not actors or made up stories.

Truth is not truth unless it is the “whole” truth,
and these health success stories and scientific studies are just as much a part of the truth
as any success story or scientific study experienced by orthodox medicine.
Free men and women are entitled to have access to
“all” the information available so they can make intelligent and informed choices in matters of their own health.
Therefore, we are sharing these success stories as an exercise of our right to freedom-of-speech and your right to freedom-of-information.
Enthusiastic Testimonials on alternatives or from our past clients can also not be seen as any assurance that you will get the same result.
The extent of the response to treatment varies from patient to patient,
even with similar diagnoses, and/or age and sex, as the internal body environment is unique to each individual patient.
Notwithstanding, the external body contamination and stresses from the past and present are also very individually unique, as will any responses, if any, to treatment.
Please also read our disclaimer, find the link at the bottom of each page.

Jun 27

Praying Through Cancer: Set Your Heart Free from Fear: A 90-Day Devotional for Women Reviews

Posted on June 27, 2011 by admin

Praying Through Cancer: Set Your Heart Free from Fear: A 90-Day Devotional for Women

Cancer can’t be explained away. No amount of Christian cliches will decrease its power. Enter Praying Through Cancer, a daily devotional written specifically for cancer patients by cancer patients with insight, wisdom, and clarity found only through personal trial. Even with cancer, an uncertain future, and a complete lack of control it is possible to experience the grace and provision of Christ’s love. The focus of each daily devotional is prayer – personal encounters with God – where fears and

List Price: $ 12.99

Price: $ 5.42

The Cure for All Cancers: Including over 100 Case Histories of Persons Cured

Cancer can now be cured, not just treated We are not accustomed to thinking about a cure for cancer. We think of remission as the only possibility. But this book is not about remission. It is about a cure. This is possible because in 1990 Dr. Clark discovered the true cause of cancer. The cause is a certain parasite, for which I have found evidence in every cancer case regardless of the type of cancer. So lung cancer is not caused by smoking, colon cancer is not caused by a low roughage diet, br

List Price: $ 24.99

Price: $ 11.94

Find More Cancer Products

Jun 14

Can you be cancer free for life and drink alcohol?

Posted on June 14, 2011 by admin

Article by Dr Laurence Magne

Can you be cancer free for life and drink alcohol?

Are you at risk?

by Dr Laurence Magne, publisher of Alternative Health Ebooks and Author of href=”http://www.cancer-free-for-life.com” target=_blank>Cancer Free for Life

Cancer kills an estimated 526,000 Americans yearly, second only to heart disease. The most common cancers in the United States are cancer of the lung, large bowel, and breast. Rothman, K.J. in Preventive Medicine 9(2):174-179, 1980, found that there is now considerable evidence to suggest a connection between heavy alcohol consumption and increased risk for cancer, with an estimated 2 to 4 % of all cancer cases thought to be caused either directly or indirectly by alcohol.

There is also a strong connection between alcohol use and cancers of the esophagus, pharynx, and mouth, whereas a more controversial association links alcohol with liver, breast, and colorectal cancers. The American Cancer Society found that together, these cancers kill more than 125,000 people annually in the United States.

Alcohol Will NOT Allow You To Be Cancer Free For Life

Research shows a link between the level of alcohol consumption and certain types of cancer. As alcohol consumption increases, so does risk of developing certain cancers, such as cancers of the upper digestive tract, the esophagus, the mouth, the pharynx, and the larynx. Other data link alcohol consumption and cancers of the liver, breast, and colon.

An estimated 75 % of esophageal cancers in the United States are attributable to chronic, excessive alcohol consumption.

Nearly 50 % of cancers of the mouth, pharynx, and larynx are associated with heavy drinking. People who drink large quantities of alcohol over time have an increased risk of these cancers as compared with abstainers. If they drink and smoke, the increase in risk is even more dramatic.

Liver. Prolonged, heavy drinking has been associated in many cases with primary liver cancer. However, it is liver cirrhosis, whether caused by alcohol or another factor, that is thought to induce the cancer. In the United States, liver cancer is relatively uncommon, afflicting approximately 2 people per 100,000, but excessive alcohol consumption is linked to as many as 36 percent of these cases. Alcohol CANNOT promote a cancer free for life.

Mechanisms of Alcohol-Related Cancers

Preliminary studies show that alcohol may affect cancer development at the genetic level by initiating and promoting cancer. Acetaldehyde, a product of alcohol metabolism, impairs a cell’s natural ability to repair its DNA, resulting in a greater likelihood that mutations causing cancer will occur.

Alcohol assists in the development of cancer

Alcohol may act as a co-carcinogen by enhancing the cancer-provoking effects of other chemicals. The risk for mouth, tracheal, and esophageal cancer is 35 times greater for people who both smoke and drink than for people who neither smoke nor drink, implying a co-carcinogenic interaction between alcohol and tobacco-related carcinogens.

Alcohol’s cancer producing effect may be explained by its interaction with enzymes that normally help to detoxify substances that enter the body. Carcinogens such as those from tobacco and diet can become more potent as they pass through the esophagus, lungs, intestines, and liver and encounter the activated enzyme.

Nutrition. Chronic alcohol abuse may result in abnormalities in the way the body processes nutrients and promote certain types of cancer. Reduced levels of iron, zinc, vitamin E, and some of the B vitamins, common in heavy drinkers, have been experimentally associated with some cancers. Also, levels of vitamin A, hypothesized to have anticancer properties, are severely depressed in the liver and esophagus during chronic alcohol consumption. For a cancer free life, just watching your diet will not reduce your chances of developing cancer in your body.

A recent study indicates that as few as two drinks per day can suppress any beneficial effects of a “correct” diet on decreasing risk of colon cancer. Although the study suggests that a diet high in folic acid, a B vitamin found in fresh fruits and vegetables, decreases the risk for colon cancer, it also warns that alcohol consumption may counter this protective action and increase the risk for colon cancer by reducing folic acid levels.

Suppression of immune response

Alcoholism has been associated with suppression of the immune system. Immune suppression makes chronic alcohol users more susceptible to various infectious diseases, and to cancer. For your best chances to remain cancer free for life, you would be best to reduce your alcohol consumption to a minimum. This means a maximum of two alcoholic beverages NO MORE than 3 times a week.

<P align=justify>For more information go tohref=”http://www.cancer-free-for-life.com” target=_blank> www.cancer-free-for-life.com.

Dr Laurence Magne

Afatinib (BIBW 2992*) Triples Progression Free Survival in Lung Cancer Patients

Posted on January 11, 2011 by admin

The results of LUX-Lung 1 in a special patient population whose cancers probably have a high incidence of EGFR mutations have substantially contributed to better understanding of the biology of these tumours. Conclusions from the trial will be relevant for the design of further clinical studies, which will evaluate further patient populations and their mutation status.